Home
About Us
About JYMed
Certificate
Download
Products
CRO Services
CDMO SERVICE
Pepitde API
Cosmetic peptide
Peptide Finished Dosage
TECHNOLOGY PLATFORMS
Peptide Synthesis Technology Platforms
Peptide Modification Platforms
Peptide Formulation Technology Platforms
JY FISTM Purification Technology Platform
Lab and Pilot Equipments
Manufacturing bases
Hubei JXBio Pharmaceutical Co.,Ltd.
Shenzhen JXBio Pharmaceutical Co.,Ltd.
Solid Quality System
News
Video
Contact Us
Home
About Us
About JYMed
Certificate
Download
Products
CRO Services
CDMO SERVICE
Pepitde API
Cosmetic peptide
Peptide Finished Dosage
TECHNOLOGY PLATFORMS
Peptide Synthesis Technology Platforms
Peptide Modification Platforms
Peptide Formulation Technology Platforms
JY FISTM Purification Technology Platform
Lab and Pilot Equipments
Manufacturing bases
Hubei JXBio Pharmaceutical Co.,Ltd.
Shenzhen JXBio Pharmaceutical Co.,Ltd.
Solid Quality System
News
Video
Contact Us
Featured
Home
Products
New Pipline
Monomethylauristatin F (MMAF)
Product Detail
Chemical Name:
(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid
Molecular Weight:
731.96
Formula:
C39H65N5O8
CAS#:
141205-32-5
Solubility:
DMSO up to 20 mM Biological Activity Monomethyl auristatin F (MMAF) or desmethyl-auristatin F is an anti-tubulin agent that inhibits cell division by blocking the polymerization of tubulin. It is a new
auristatin
derivative
with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, monomethyl auristatin E (MMAE). In addition, the N-terminal amino group has only
one
methyl substituent instead of two as in
auristatin F
itself.
Product Tags
Monomethylauristatin F;MMAF
Monomethylauristatin F (MMAF) Related Video:
Related Products
Monomethyl Auristatin E (MMAE)